Department: Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE)

Phone: +34 966 658 727

Email: aferrer@umh.es

ResearchGate: Antonio Ferrer Montiel

Current Position: Director of the Instituto de Biología Molecular y Celular (IBMC), Universidad Miguel Hernández.

​

Research Fields

• Molecular dermatology: sensitive skin pathophysiology.

• Chronic Pain mechanisms.

• Pain and pruritus therapeutics.

Representative Publications

• Ciardo MG, Andrés-Bordería A, Cuesta N, Valente P, Camprubí-Robles M, Yang J, Planells-Cases R, Ferrer-Montiel A. Whirlin increases TRPV1 channel expression and cellular stability. Biochimica et Biophysica Acta. (2016) Jan;1863(1):115-27. doi: 10.1016/j.bbamcr.2015.10.016.

​​

• Mathivanan S, Devesa I, Changeux JP, Ferrer-Montiel A. Bradykinin Induces TRPV1 Exocytotic Recruitment in Peptidergic Nociceptors. Frontiers in Pharmacology (2016) Jun 23;7:178. doi: 10.3389/fphar.2016.00178. eCollection 2016 Jun 23.

​​

• Devesa I, Wolf C, Mathivanan S, Ferrandiz-Huertas C, Lujan R, Changeux J.-P. and Ferrer-Montiel A. α-CGRP is essential for pro-algesic sensitization of TRPV1 in peptidergic C-type nociceptors. Proceedings of the National Academy of Sciences of the U.S.A. (2014) 111, 18345-18350.

​​

• Taberner F, López-Cordoba A, Fernandez-Ballester G, Korchev and Ferrer-Montiel A.The S6-TRPbox linker domain in TRPM8 plays a central role in allosteric channel activation. The Journal of Biological Chemistry (2014) 289, 28579-28594.

​​

• Gregorio-Teruel L, Valente P, González-Ros JM, Fernandez-Ballester G and Ferrer-Montiel A. Mutation of I696 and W697 in the TRP box of vanilloid receptor subtype modulate allosteric channel activation. The Journal of General Physiology (2014) 143, 361-375.

​​

• Devesa I, Fernández-Ballester G, Ferrer-Montiel A. Targeting protein-protein interactions to rescue DF508-CFTR: a novel corrector approach to treat cystic fibrosis. EMBO Molecular Medicine (2013) 5, 1-4.

​

• Valente, P, Fernández-Carvajal A, Camprubí-Robles M, Gomis A, Fernandez-Ballester G, Viana F, Gonzalez Ros JM, Belmonte C, Planells-Cases, R, Ferrer-Montiel A. Membrane-tethered peptides patterned after the TRP domain (TRPducins) selectively inhibit TRPV1 channel activity. The FASEB Journal (2011) 25, 1628-1640.

Patents and Available Technologies

• Blanes C, Llobregat M, Gil A, Fernández-Ballester G, Planells Cases R, Viniegra S, Gutierrez LM, Carbonell T, Pérez-Payá E, Ferrer-Montiel. A. Neuronal exocytosis inhibiting peptide and cosmetic composition and pharmaceutical composition containing the peptide. US77473679 B1 (granted on 21/03/2006).  Producto cosmeceutico Argireline®, explotado por LIPOTEC SAU.

​​

• Cristina Carreño, Berta Ponsati, Wim Van Den Nest, Jimena Fernández, María Camprubí Robles, Antonio Ferrer‑Montiel. Compositions for the treatment of pain and/or inflammation. WO2010/009892 A2. Producto DD04107. Desarrollo clínico por BCN Peptides.

​​

• Antonio Ferrer‑Montiel, Asia Fernández-Carvajal, Carlos Belmonte Martínez, Félix Viana, Juana Gallar, Pharmaceutical composition for the treatment of dry eye. WO2012/032209 A3. Formulación producto WS-12. Desarrollo clínico AvizoRx.

​​

• Antonio Ferrer Montiel, Gregorio Fernández Ballester, José María García Antón, Cristina Carreño,Núria Almiñana, Raquel Delgado. Compounds which inhibit neuronal exocytosis. WO2013153196 (A1). Desarrollo cosmecéutico L´OREAL.

​​

• Antonio Ferrer Montiel, A. Fernández-Carvajal, R. de la Torre, M.A. Juana Gallar, Carlos Belmonte, Gian Cesare Tron, Valentina Mercali, Armando Genazzani. Compuestos agonistas del receptor trpm8 y sus aplicaciones, UMH. PCT/ES2017/070026

​​

• Antonio Ferrer Montiel, A. Fernández-Carvajal, Isabel Devesa, Tracey Pirali, Armando Genazzani. TRPV1 modulator compounds. AntalGenics SL. EP17382266

Company Agreements

• Lipotec

• Angelini

• AntalGenics

Spin-off companies

• Fastbase Solutions (2015-present)

• AntalGenics (2015-present)

• Prospera Biotech (2014-present)

• Diverdrugs (1999-2012)